Background: No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC. We studied the activity of EGFR antagonists alone, and in combination with chemotherapy, in TNBC cell lines.
expression was observed in 54% of cases positive for basal cytokeratins. EGFR expression was also associated with poor survival, independent of nodal status and size [3] .
EGFR inhibitors currently in clinical use include the small molecule tyrosine kinase inhibitors gefitinib and erlotinib and the mAb cetuximab, which are approved for treatment of a number of solid tumours [9, 10] . In this study, we have investigated EGFR inhibition as a therapeutic option in the treatment of TNBC.
materials and methods cells and reagents
Three TNBC cell lines (BT20, HCC1937, MDA-MB-231) and two HER-2 overexpressing cell lines (BT474, SKBR3) were obtained from the American Tissue Culture Collection, Manassas, VA. Cell lineswere maintained in RPMI-1640 with 10% fetal bovine serum (BioWhittaker, Walkersville, MD), at 37°C with 5% CO 2 . HCC1937 medium was supplemented with 1% sodium pyruvate (Sigma, Aldrich, Wicklow, Ireland). Gefitinib (Iressaä, Astrazeneca), cetuximab (Erbituxä, Merck), docetaxel (Taxotereä, Aventis), carboplatin (Paraplatinä, Bristol-Myers Squibb) and doxorubicin (Adriamycinä, Pharmacia & UpJohn) were purchased from the Pharmacy Department, St Vincent's University Hospital, Dublin. Erlotinib was purchased from Sequoia Research Products (Pangbourne, UK). Western blotting was carried out using anti-MAPK, anti-phospho-MAPK, anti-Akt, anti-phospho-Akt, anti-phospho-tyrosine (Cell Signalling Technology, Danvers, MA), anti-EGFR (Lab Vision, Fremon, CA), anti-a-tubulin (Sigma) antibodies, secondary anti-mouse antibody (Sigma) and antirabbit antibody (Pierce Biotechnology, Rockford, IL).
protein extraction
After 48-h gefitinib treatment, cells were washed with ice-cold phosphatebuffered saline (PBS) and lysed in 500 ll RIPA buffer (Sigma) containing protease inhibitors, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mM sodium orthovanadate. After 20-min incubation on ice, lysate was passed through a 21-gauge needle and centrifuged at 16 100·g for 5 min at 4°C. Protein quantification was carried out using the bicinchoninic acid assay (Pierce).
enzyme-linked immunosorbent assay
EGFR and phosphorylated epidermal growth factor receptor (P-EGFR) were measured by enzyme-linked immunosorbent assay (ELISA). One microgram of protein (TNBC cell lines) or 5 lg protein (HER-2-positive cell lines) was used for the EGFR ELISA (R&D Systems, Minneapolis, MN). EGFR protein concentrations were estimated from a standard curve and expressed as pg EGFR per lg of total protein. For P-EGFR, TNBC cells were serum starved for 24 h and treated with serum-free medium (control), 10 ng/ml epidermal growth factor (EGF) for 10 min or 1 lM gefitinib for 15 min followed by 10 ng/ml EGF for 10 min. One microgram (BT20) or 5 lg (HCC1937, MDA-MB-231) protein was tested in the P-EGFR ELISA (R&D Systems). P-EGFR levels were expressed relative to control untreated cells.
western blotting
Twenty micrograms of protein in sample buffer was heated to 95°C for 5 min and proteins were separated using 7.5% or 10% polyacrylamide gels (Cambrex, East Rutherford, NJ). Protein was transferred to Hybondenhanced chemiluminescence nitrocellulose membrane (Amersham Biosciences, Buckinghamshire, UK) and the membrane was blocked with 3% blocking solution (3% milk powder/PBS-0.1% Tween) at room temperature for 1 h. After overnight incubation at 4°C with primary antibody in 1% blocking solution, three washes with PBS-0.1% Tween were carried out followed by incubation at room temperature with secondary antibody in 3% blocking solution for 1 h. Following three washes with PBS-0.1% Tween and one PBS wash, protein bands were detected using Luminol (Santa Cruz Biotechnology Inc., Santa Cruz, CA) or ECLAdvance (Amersham Biosciences). Total EGFR was immunoprecipitated using anti-EGFR antibody (Labvision), and P-EGFR was detected using anti-phospho-tyrosine antibody (Cell Signalling). 
proliferation assays

statistical analysis
For fixed dose gefitinib combination assays, a two-tailed t-test was used to compare the effect of gefitinib combined with chemotherapy with the chemotherapy drug alone. For triple combination fixed ratio assays, combination indices (CIs) at the ED 50 (effective dose of combination that inhibits 50% of growth) were determined using the Chou and Talalay equation [11] , on CalcuSyn software (Biosoft, Cambridge, UK). CI < 1 implies synergy, CI = 1 implies additivity and CI > 1 implies antagonism. Percentages of cells in each phase of the cell cycle in drug-treated cells were compared with untreated cells using a two-tailed t-test. P <0.05 was considered statistically significant.
results
EGFR inhibition
High levels of EGFR were detected in the TNBC cell lines (pg EGFR per lg total protein: BT20, 150.5 6 11.7; HCC1937, 44.4 6 8.1; MDA-MB-231, 72.1 6 9.8) compared with the HER-2-positive cell lines, which overexpress HER-2 [12] , but have low levels of EGFR (pg EGFR per lg total protein: BT474, 3.6 6 1.1; SKBR3, 20.5 6 2.5). Despite high levels of EGFR expression, the TNBCs were less sensitive to gefitinib and erlotinib than the HER-2-positive cell lines (Table 1) . Gefitinib was the most effective EGFR inhibitor tested, with HCC1937 the most sensitive of the TNBC cell lines [drug concentration which inhibits 50% of cell growth (IC 50 ): 8.4 6 1.5 lM]. Cetuximab showed very little effect on proliferation in any of the cell lines tested. No significant difference in chemosensitivity, to the three Figure 1A) . Similar results were obtained for MDA-MB-231, but with a higher concentration of gefitinib, as this cell line is less sensitive to gefitinib (supplemental Figure 1, available online) .
Treatment with the triple combination of gefitinib, carboplatin and docetaxel was also more effective in BT20 and HCC1937 cells than each agent alone ( Figure 1B) . CI values for the triple combination suggest a synergistic interaction in both cell lines (BT20, CI at ED 50 = 0.5 6 0.1; HCC1937, CI at ED 50 = 0.8 6 0.4), while the chemotherapy combination alone is slightly antagonistic (BT20, CI at ED 50 = 1.2 6 0.2; HCC1937, CI at ED 50 = 1.3 6 0.1).
effects of gefitinib on EGFR signalling and cell cycle arrest P-EGFR was detected at high levels in BT20 cells and was reduced in response to gefitinib treatment. Low levels of original article Annals of Oncology P-EGFR were detected in MDA-MB-231 and HCC1937 cells by western blot (Figure 2A ). However, EGF treatment, following serum starvation, significantly increased phosphorylation of EGFR in all three TNBC cell lines and gefitinib treatment efficiently blocked EGF-induced phosphorylation of EGFR ( Figure 2B ). Gefitinib decreased phosphorylation of MAPK and Akt in the sensitive HER-2-positive cell lines, BT474 and SKBR3. Gefitinib treatment also reduced phosphorylation of both MAPK and Akt in HCC1937, which is the most sensitive of the TNBC cell lines. Gefitinib decreased phosphorylation of MAPK in BT20 cells but no change in Akt phosphorylation was observed. No change in phosphorylation of MAPK was observed in MDA-MB-231 cells and consistent with previous results, phosphorylated Akt was not detected in MDA-MB-231 cells [13] .
Response to EGFR inhibition is associated with induction of G 1 cell cycle arrest [14, 15] . A significant increase in G 1 was observed in BT474 and SKBR3 cells treated with 10 lM gefitinib for 48 h ( Table 2 ). In contrast, no increase in G 1 was observed in either BT20 or MDA-MB-231 cells treated with 10 lM gefitinib. A small increase in G 1 was observed in the HCC1937 cells in response to 10 lM gefitinib but this increase did not achieve statistical significance. Treatment with Figure 2 . (A) Detection of EGFR, P-EGFR, MAPK, P-MAPK, Akt and P-Akt in triple-negative breast cancer and HER-2-positive cell lines treated with gefitinib for 48 h. (G: gefitinib; P-: phospho-; EGFR IP P-tyr: epidermal growth factor receptor immunoprecipitation, followed by phospho-tyrosine immunoblotting.). (B). Levels of phosphorylated epidermal growth factor receptor (P-EGFR) in epidermal growth factor-stimulated TNBC cells with and without gefitinib pretreatment, compared with untreated cells. P-EGFR levels were measured by enzyme-linked immunosorbent assay. (C) Analysis of the effects of 48 h of treatment with 10 lM G alone, 10 lM P and 1 nM D and the three drugs combined, on cell cycle progression in BT20 and HCC1937. P values were calculated for each treatment compared with untreated cells, using a two-tailed t-test.
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carboplatin and docetaxel caused a significant increase in G 2 , with an associated decrease in G 1 , in BT20 and HCC1937 cells ( Figure 2C , supplemental Table 1 , available online). The combination of gefitinib with carboplatin and docetaxel induced similar G 2 arrest and an increase in G 1 compared with the chemotherapy drugs alone, which was significant in the HCC1937 cells (BT20, P = 0.162; HCC1937, P = 0.009). The sub-G 0 /G 1 fraction was increased in HCC1937 cells treated with the chemotherapy doublet (P = 0.004) and the triple combination (P = 0.086), compared with untreated cells (supplemental Table 1 , available online).
discussion
Our data confirm the observation that EGFR is overexpressed in TNBC [2, 3, 16, 17] . The lack of a proven targeted therapy for TNBC, together with the availability of a number of approved EGFR inhibitors, provides a powerful rationale for the study of these agents, alone and in combination with chemotherapy in TNBC. While our data confirm the activity of the EGFR inhibitor gefitinib in TNBC cell lines, we found higher activity for this agent in HER-2-positive breast cancer cell lines, despite the fact that these cells had lower levels of EGFR. Cetuximab showed no inhibition of growth of the TNBC cell lines tested in this study. Lack of efficacy of cetuximab in breast cancer cells in vitro has previously been reported [18] . Hoadley et al. [18] identified a basal-like breast cancer cell line (SUM102) which displayed sensitivity to both cetuximab and gefitinib. The SUM102 cell line has previously been shown to be dependent on EGFR for growth [19] . TNBC cell lines can also be divided into basal-like and post-epithelial mesenchymal transition (EMT) or basal-A and basal-B [20] [21] [22] . The BT-20 and HCC1937 cells are classified as basal like or basal-A while the MDA-MB-231 cells which show greatest resistance to gefitinib are classified as post-EMT or basal-B. EMT has been implicated in resistance to EGFR inhibition in lung cancer [23, 24] and may contribute to the gefitinib resistance observed in the MDA-MB-231 cells.
In the TNBC cell lines studied, significant levels of P-EGFR were only detected in BT20 cells. Very low levels of P-EGFR were detected in MDA-MB-231 and HCC1937 cells, by immunoblotting. This suggests that despite high levels of EGFR protein in TNBC cells, they may not be dependent on EGFR signalling for growth and this may explain their relative resistance to EGFR inhibition, compared with the HER-2-positive cell lines, at least in vitro. Although basal levels of P-EGFR in TNBC cells were low, EGF treatment induced significant phosphorylation of EGFR and gefitinib efficiently blocks the phosphorylation of EGFR in EGF-treated TNBC cells. Measurement of the phosphorylation status of EGFR in triple-negative tumours may help to clarify if TNBCs are dependent on EGFR signalling.
Phosphorylation of both MAPK and Akt were reduced in the gefitinib-sensitive, HER-2 overexpressing BT474 and SKBR3 cell lines in response to gefitinib. HCC1937 cells, which show the greatest sensitivity to gefitinib, also showed reduced phosphorylation of both MAPK and Akt. In BT20 cells, a decrease in phosphorylation of MAPK was observed with no change in phosphorylated Akt. No changes in either MAPK or Akt phosphorylation were observed in MDA-MB-231 cells. This suggests that response to EGFR inhibition requires efficient blockade of both MAPK and Akt signalling.
Although the TNBC cells are not inherently sensitive to EGFR inhibition, combined treatment with gefitinib and chemotherapy has a greater effect on proliferation than either gefitinib or the chemotherapy alone. Using CI, we have shown that the triple combination of gefitinib with carboplatin and docetaxel is synergistic in the TNBC cells. This synergy may be partly due to synergy between gefitinib and the individual chemotherapy drugs. However, the dual combination of carboplatin and docetaxel appears to be antagonistic while the addition of gefitinib results in synergy. Hoadley et al. [18] also showed that combinations of cetuximab or gefitinib with chemotherapy were synergistic in the basal-like breast cancer cell line SUM102.
Similar interactions between gefitinib and chemotherapy have been observed in the HER-2-positive SKBR3 and BT474 cells lines [25] . Pegram et al. [26] also showed that the triple combination of trastuzumab, carboplatin and docetaxel was highly synergistic in HER-2-positive breast cancer cells and this combination has shown efficacy in the treatment of early-stage HER-2-positive breast cancer [27] .
Combined induction of G 2 /M and G 1 arrest observed for treatment with gefitinib, carboplatin and docetaxel may, at least in part, explain the synergy observed with the triple combination in the TNBC cell lines. An increase in the sub-G 0 / G 1 fraction was also observed with the chemotherapy combination and the triple combination, suggesting an increase in apoptosis.
Despite their relative resistance to gefitinib, our data show that combination of gefitinib with carboplatin and docetaxel improves response in the TNBC cell lines. Although the concentrations of gefitinib used in our in vitro assays are high, evidence from the BCIRG103 study suggests that a preferential distribution of gefitinib from blood into tumour tissue occurs in vivo [28] . Following treatment of breast cancer patients with oral gefitinib (250 mg/day for at least 14 days, n = 19), gefitinib concentrations in breast tumour tissue (mean = 16.7 lM) were 42 times higher than plasma concentrations.
Previous single-agent clinical trials in breast cancer with EGFR inhibitors, in general, have been disappointing. However, these have often been in heavily pretreated and unselected patient populations [29, 30] . Our results suggest that the triple combination of gefitinib with docetaxel and carboplatin is a rational combination that may provide additional benefit in TNBC patients and warrants further investigation. references
